Gene Expression Analysis for COPD Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and managing chronic obstructive pulmonary disease (COPD) are inadequate, particularly in cases where bronchoscopy procedures yield indeterminate or non-diagnostic results, leading to delayed or inaccurate assessments and treatments.
Innovation Solution
The use of gene expression analysis to assess COPD status by evaluating the expression levels of informative-genes in biological samples obtained during routine cell or tissue sampling procedures, enabling the calculation of COPD risk scores and guiding diagnostic and therapeutic interventions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If bronchoscopy procedures are performed to diagnose COPD, then diagnostic information can be obtained, but the procedures often yield indeterminate or non-diagnostic results
Solution Approach 1:
The diagnostic process is segmented into multiple independent assessment components: histological evaluation of tissue samples, gene expression analysis of respiratory epithelium, and clinical symptom assessment. This segmentation allows the gene expression component to provide diagnostic information independently when histological evaluation is inconclusive, thereby reducing information loss from indeterminate bronchoscopy results.
Solution Approach 2:
Gene expression analysis serves as an intermediary diagnostic tool between traditional histological bronchoscopy and clinical diagnosis. When histological samples appear normal or indeterminate, the gene expression profile of respiratory epithelium acts as a mediator to reveal underlying COPD pathology that is not visible through conventional histological methods alone.
2Loss of time
If traditional diagnostic methods are used for COPD, then standard procedures can be followed, but early and accurate diagnosis is delayed
Solution Approach 1:
Gene expression analysis is performed on respiratory epithelium samples obtained during routine bronchoscopy procedures before final diagnostic conclusions are reached. This preliminary molecular assessment allows clinicians to identify COPD early in the diagnostic workflow, potentially before invasive procedures or extended monitoring are required, thereby reducing both time loss and improving accuracy.
Solution Approach 2:
The patent replaces reliance solely on mechanical/histological evaluation of tissue samples with molecular-level gene expression analysis. This substitution enables detection of COPD at the molecular level in respiratory epithelium, providing earlier and more accurate diagnosis than traditional histological methods alone can achieve.
3Loss of information
If gene expression analysis is performed on histologically normal tissue, then actionable information can be obtained from uninformative bronchoscopies, but additional testing complexity is introduced
Solution Approach 1:
The gene expression analysis platform serves multiple diagnostic functions: it evaluates histologically normal tissue for molecular signs of COPD, assesses indeterminate cases, and provides prognostic information. This multi-functionality allows the same testing approach to extract actionable information from various types of bronchoscopy samples, maximizing the utility of routine procedures while managing complexity through a unified molecular assessment approach.
Data Source
AI summary
The invention in some aspects provides methods of determining the likelihood that a subject has COPD based on the expression of informative-genes. In other aspects, the invention provides methods for determining an appropriate diagnostic intervention plan for a subject based on the expression of informative-genes. Related compositions and kits are provided in other aspects of the invention.